UCB (OTCMKTS:UCBJY) Downgraded by Zacks Research to “Hold”

UCB (OTCMKTS:UCBJY) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

A number of other equities research analysts also recently commented on the stock. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, UCB has an average rating of “Moderate Buy”.

UCB Price Performance

UCBJY opened at $119.73 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The firm has a 50 day moving average price of $128.90 and a 200-day moving average price of $140.10. UCB has a twelve month low of $114.53 and a twelve month high of $168.76.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.